Literature DB >> 1729374

IFN-gamma-induced L-arginine-dependent toxoplasmastatic activity in murine peritoneal macrophages is mediated by endogenous tumor necrosis factor-alpha.

J A Langermans1, M E Van der Hulst, P H Nibbering, P S Hiemstra, L Fransen, R Van Furth.   

Abstract

Activated murine peritoneal macrophages inhibit the intracellular proliferation of Toxoplasma gondii and produce a number of cytokines, such as TNF-alpha and IL-1. Both TNF-alpha and IL-1 have been reported to be involved in the immune response against various microorganisms, but the mechanisms responsible for these effects are not known. In the present study it was investigated whether endogenously produced TNF-alpha and IL-1 are involved in the activation of peritoneal macrophages by rIFN-gamma leading to toxoplasmastatic activity and the production of reactive nitrogen intermediates. The rIFN-gamma-induced toxoplasmastatic activity was inhibited by neutralizing antibodies against mouse TNF-alpha in a dose-dependent and time-dependent way, but neutralizing antibodies against mouse IL-1 alpha and IL-1 beta did not affect this activity. Involvement of TNF-alpha in the induction of toxoplasmastatic activity was confirmed by our finding that rTNF-alpha in combination with a nonactivating concentration of rIFN-gamma inhibited the intracellular proliferation of T. gondii. No synergistic activity of rIL-1 and rIFN-gamma on the inhibition of T. gondii proliferation was found. Both rTNF-alpha and rIL-1 alpha alone inhibited the intracellular proliferation of T. gondii only slightly. Because it has been reported recently that activated macrophages produce reactive nitrogen intermediates that are essential in the induction of toxoplasmastatic activity, we investigated whether these intermediates are involved in the TNF-dependent induction of toxoplasmastatic activity. Neutralizing antibodies against mouse TNF-alpha inhibited also the release of NO2- by rIFN-gamma-activated macrophages almost completely. Macrophages incubated with rTNF-alpha in combination with a nonactivating concentration of rIFN-gamma released substantial amounts of NO2-, but rTNF-alpha and rIL-1 alpha alone, and the combination of rIL-1 alpha and a nonactivating concentration of rIFN-gamma induced only little NO2(-)-release by macrophages. To assess whether reactive nitrogen intermediates act directly or indirectly on the intracellular proliferation of T. gondii, macrophages were incubated with the L-arginine analog NG-monomethyl-L-arginine or the NADPH-inhibitor diphenylene iodonium, both inhibitors of the generation of reactive nitrogen intermediates. Good correlation was found between toxoplasmastatic activity and the release of NO2- during the 24-h activation period before infection of the macrophages with T. gondii, but no correlation was found between toxoplasmastatic activity and the release of NO2- during infection of the macrophages.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1729374

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  84 in total

1.  Alteration of T cell subtypes in spleen and antibodies of serum in mice infected with Angiostrongylus cantonensis.

Authors:  Haijuan Liu; Xiaodong Luo; Erxia Shen; Hua Li; Xue Ding; Daixiong Chen
Journal:  Parasitol Res       Date:  2013-01-16       Impact factor: 2.289

2.  The contributions of reactive oxygen intermediates and reactive nitrogen intermediates to listericidal mechanisms differ in macrophages activated pre- and postinfection.

Authors:  S Ohya; Y Tanabe; M Makino; T Nomura; H Xiong; M Arakawa; M Mitsuyama
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

3.  Inhibitory effect of nitric oxide on the replication of a murine retrovirus in vitro and in vivo.

Authors:  K Akarid; M Sinet; B Desforges; M A Gougerot-Pocidalo
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

4.  BALB/c mice resistant to Toxoplasma gondii infection proved to be highly susceptible when previously infected with Myocoptes musculinus fur mites.

Authors:  Aurea Welter; José Roberto Mineo; Deise Aparecida de Oliveira Silva; Elaine Vicente Lourenço; Eloísa Amália Vieira Ferro; Maria Cristina Roque-Barreira; Neide Maria da Silva
Journal:  Int J Exp Pathol       Date:  2007-10       Impact factor: 1.925

5.  Influence of macrophage resistance gene Lsh/Ity/Bcg (candidate Nramp) on Toxoplasma gondii infection in mice.

Authors:  J M Blackwell; C W Roberts; T I Roach; J Alexander
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

6.  Group B streptococcus-induced nitric oxide production in murine macrophages is CR3 (CD11b/CD18) dependent.

Authors:  K J Goodrum; L L McCormick; B Schneider
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

7.  Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages.

Authors:  J S Silva; G N Vespa; M A Cardoso; J C Aliberti; F Q Cunha
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

8.  Tumor necrosis factor alpha acts as an autocrine second signal with gamma interferon to induce nitric oxide in group B streptococcus-treated macrophages.

Authors:  K J Goodrum; J Dierksheide; B J Yoder
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  Mycobacterial 65-kilodalton heat shock protein induces tumor necrosis factor alpha and interleukin 6, reactive nitrogen intermediates, and toxoplasmastatic activity in murine peritoneal macrophages.

Authors:  W E Peetermans; C J Raats; R van Furth; J A Langermans
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

10.  Opposing effects of interferon-gamma on iNOS and interleukin-10 expression in lipopolysaccharide- and mycobacterial lipoarabinomannan-stimulated macrophages.

Authors:  T I Roach; C H Barton; D Chatterjee; F Y Liew; J M Blackwell
Journal:  Immunology       Date:  1995-05       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.